Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. Miura S, Koh Y, Azuma K, Yoshioka H, et al. BMC Cancer 2023;23:6.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Miura S, Koh Y, Azuma K, Yoshioka H, et al. Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC Cancer 2023;23:6.
PMID: 36597021